Overview

ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
0
Participant gender:
All
Summary
Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allysta Pharmaceutical
Treatments:
Ophthalmic Solutions
Criteria
Inclusion Criteria:

- Dry eye disease for > 3 months meeting specific sign and symptom criteria

- Best corrected visual acuity of +0.6 logMAR or better

- Willing to sign informed consent and attend study visits

- Willing to comply with contraception requirements

Exclusion Criteria:

- Unable to meet specific sign and symptom criteria

- Signs of ophthalmic allergic, inflammatory or infection conditions

- Use of contact lenses

- Anatomic abnormalities preventing accurate study assessments

- Use of medications that influence eye dryness

- Recent ophthalmic surgery

- Unwilling to suspend current treatments for dry eye disease